Shares of NATCO Pharma Ltd on Thursday slumped 20 per cent after the firm reported a 37.75 per cent decline in consolidated net profit in the December quarter. The stock tanked 19.86 per cent to ...

Shares of NATCO Pharma tumbled another 10% in intra-day trade on Friday, February 14, extending its slide to the sixth straight session. The stock had tumbled 20% on Thursday as well following the ...

Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third quarter financial results. Natco Pharma Ltd. shares tanked during the ...

Image Source : PIXABAY The counter opened gap down with a loss of 18.96 per cent. NATCO Pharma share price: The shares of NATCO Pharma Ltd, a constituent of BSE 500, tanked 20 per cent on Thursday ...

NATCO Pharma Ltd reported a 37.75 per cent decline in consolidated net profit to ₹132.4 crore for Q3 FY2025, down from ₹212.7 crore in the same quarter last year. The company’s shares ...

Natco Pharma, a Telangana-based pharmaceutical company, saw its shares plummet to the abyss, losing double digits (over 19 per cent) in the intraday trade on Thursday, February 13. This major ...

Shares of Natco Pharma were battered in trade on February 13, plunging as much as 18.5 percent as investors dumped the stock following its disappointing Q3 earnings performance. The drugmaker's ...

Natco Pharma Q3 Results 2025:Natco Pharma declared their Q3 results on 12 Feb, 2025, revealing a significant decline in both revenue and profit. The company reported a profit of ₹133 crore ...

Natco Pharma Ltd has received final approval from the USFDA to market Bosentan 32mg tablets. This drug, Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension (PAH).

The company had posted a consolidated net profit of Rs 212.7 crore in the third quarter of the previous fiscal year, NATCO Pharma said in a regulatory filing. Consolidated revenue from operations in ...